Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 26, 2005. The report primarily addresses a significant tax dispute with the US Internal Revenue Service (IRS) and discloses changes in directors' interests regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The only financial figures disclosed relate to the tax dispute:
- New Tax Claim (1997-2000): $1.9 billion (approximately £1.0 billion).
- Estimated Interest on New Claim: Approximately $700 million (approximately £380 million), net of federal tax relief.
- Prior Tax Claim (1989-1996): $2.7 billion in tax with an estimated interest charge of $2.5 billion.
Material Changes and Contingencies
The primary material event is the receipt of a Notice of Deficiency from the IRS regarding tax allocation disputes for the years 1997-2000. This follows a similar notice for the 1989-1996 period announced in January 2004. The dispute centers on the allocation of taxes on profits for Glaxo heritage products between the US and other countries. GSK disagrees with the claim, asserting it has paid all taxes owed and that the IRS's position is inconsistent with the treatment of other pharmaceutical companies.
Outlook, Management Commentary, and Risks
Management states that GSK believes it has made adequate provision for tax liabilities arising from these assessments. The company plans to contest the claim and intends to ask the US Tax Court to consolidate the 1997-2000 claim with the pending case for the 1989-1996 tax years. A provisional trial date has been set for October 2006. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the adequacy of GSK's existing financial provisions against the total potential liability of the combined tax claims ($1.9 billion + $2.7 billion) plus interest.
- Monitor the status of the US Tax Court proceedings, specifically the consolidation of the 1997-2000 and 1989-1996 cases.
- Review the "Risk Factors" section of the 2003 Annual Report on Form 20-F for detailed operational risks.
- Confirm the impact of the tax dispute on future cash flows and potential interest accruals beyond the current estimates.